Fusion Pharmaceuticals Inc. (FUSN)

NASDAQ: FUSN · IEX Real-Time Price · USD
4.90
-0.12 (-2.39%)
At close: Jun 2, 2023, 4:00 PM
4.99
+0.09 (1.84%)
After-hours: Jun 2, 2023, 7:20 PM EDT
-2.39%
Market Cap 312.85M
Revenue (ttm) 904,000
Net Income (ttm) -91.99M
Shares Out 63.85M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 92,261
Open 4.97
Previous Close 5.02
Day's Range 4.85 - 5.29
52-Week Range 1.98 - 5.29
Beta -1.14
Analysts Strong Buy
Price Target 9.20 (+87.76%)
Earnings Date May 11, 2023

About FUSN

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-l... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2020
Employees 106
Stock Exchange NASDAQ
Ticker Symbol FUSN
Full Company Profile

Financial Performance

In 2022, FUSN's revenue was $1.46 million, an increase of 1.46% compared to the previous year's $1.44 million. Losses were -$87.61 million, 8.10% more than in 2021.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for FUSN stock is "Strong Buy." The 12-month stock price forecast is $9.2, which is an increase of 87.76% from the latest price.

Price Target
$9.2
(87.76% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference

HAMILTON, ON and BOSTON , May 31, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...

2 days ago - PRNewsWire

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update   Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society of Nuclear Medicine and Molecular Imagi...

3 weeks ago - PRNewsWire

Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

HAMILTON, ON and BOSTON , May 9, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...

3 weeks ago - PRNewsWire
}

Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer

Facility is on track to be fully operational in 2024 HAMILTON, ON , May 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next...

1 month ago - PRNewsWire

Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

HAMILTON, ON and BOSTON , April 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre...

1 month ago - PRNewsWire

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual Meeting

FPI-2059 induces tumor growth inhibition in colorectal tumor model TEM-1 and EGFRvIII demonstrate potential as TAT targets HAMILTON, ON and BOSTON , April 19, 2023 /PRNewswire/ -- Fusion Pharmaceutica...

1 month ago - PRNewsWire

Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines

1 month ago - PRNewsWire

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAMILTON, ON and BOSTON, April 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...

2 months ago - PRNewsWire
}

Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1

HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

2 months ago - PRNewsWire

Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates

Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expecte...

2 months ago - PRNewsWire

Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference

HAMILTON, ON and BOSTON , March 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

3 months ago - PRNewsWire

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer

Acquisition of Phase 2 program with established clinical proof of concept strengthens pipeline of innovative targeted alpha therapies In connection with the transaction, Fusion announces $60.0 million...

3 months ago - PRNewsWire

Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

HAMILTON, ON and BOSTON , Feb. 13, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

3 months ago - PRNewsWire
}

Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights

FPI-2068 IND expected to be submitted in the first quarter of 2023 FPI-1434 Phase 1 data expected in the second quarter of 2023 FPI-1966 Phase 1 study open and enrolling patients; Company expects to p...

5 months ago - PRNewsWire

Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

-  Agreement augments Fusion's existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows -  Furthers BWXT Medical's position as a global leader in medical isotope...

Other symbols: BWXT
5 months ago - PRNewsWire

Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates

FPI-1434 Phase 1 data on track to be reported in first half of 2023 Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expressing FGFR3 Strong balance sheet with $205.5 million ...

7 months ago - PRNewsWire

Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer

HAMILTON, ON and BOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...

7 months ago - PRNewsWire

Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

HAMILTON, ON and BOSTON , Sept. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

9 months ago - PRNewsWire

Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3

HAMILTON, ON and BOSTON , Aug. 29, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

9 months ago - PRNewsWire

Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates

FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted alpha therapy Data supporting ongoing evaluation of cold antibody pre-administration dosing regimen in...

10 months ago - PRNewsWire

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1

HAMILTON, ON and BOSTON , June 23, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

1 year ago - PRNewsWire

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

- Study evaluates pre-administration of cold antibody prior to administration of imaging agent - Imaging shows favorable gain in tumor lesion uptake versus normal tissue when cold antibody is pre-admi...

1 year ago - PRNewsWire

Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement

Fusion to invest $5M for guaranteed access to actinium-225 supply Agreement augments Fusion's existing supply as company expands pipeline of actinium-based radio pharmaceuticals HAMILTON, ON and BOSTO...

1 year ago - PRNewsWire

Fusion's stock falls 4% after announcing two clinical delays

Shares of Fusion Pharmaceuticals Inc. FUSN, -0.54% fell 4.3% in premarket trading on Thursday after the company announced several delays to its oncology program. Fusion said it wouldn't be able to sha...

1 year ago - Market Watch

Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs

HAMILTON, ON and BOSTON , June 9, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...

1 year ago - PRNewsWire